The Labor Department said Wednesday that the producer price index, which tracks prices before they reach consumers, rose 0.2% in January. That followed a 0.1% increase in December and a flat reading in November. In the past year, producer prices have risen just 1.2%, below the Federal Reserve's preferred target rate.
Excluding the cost of food, energy and markups by wholesalers and retailers, so-called core prices ticked up just 0.1%.
January's producer prices are the first to be compiled since the government revamped its index to make it more comprehensive. Producer prices now include services and construction. Before last month, the index tracked only goods.
Top 10 Healthcare Technology Companies To Own In Right Now: California Grapes International Inc (CAGR)
California Grapes International, Inc., formerly China Food Services, Corp., incorporated in 1992, conducts its primary business operations as an importer, exporter and distributor of staple, organic, specialty, and gourmet foods and beverages, catering to the Asian Pacific Rim. The Company owns and operates Golden Dragon Food & Beverage Import & Export Company of Hong Kong, Ltd. (GDHK) in central Hong Kong and Beijing Flying Golden Dragon International Trading Co., Ltd. in China (BFGD). Golden Dragon Holdings, Inc. has agreements with the United State food manufacturers. It acts as a buying agent for GDHK, negotiating vendor contracts and services with the United States food and beverage industry partners.
The Company focuses to offer wholesale food distribution to grocery chains and independent food stores throughout China. The Company focuses on purchasing goods directly from manufactures in the United States, Latin America and Europe, and distributes these products to distributors, grocery stores, supermarkets and hypermarkets throughout China.
Advisors' Opinion:- [By ovenerio]
As we can see in the next chart, the stock price has an upward trend in the five-year period. If you had invested $10,000 five years ago, today you could have $23,305, which represents a 18.4% compound annual growth rate (CAGR).
- [By Omar Venerio]
As we can see in the next chart, the stock price has an upward trend in the five-year period. If you had invested $10,000 five years ago, today you could have $17,891, which represents a 12.3% compound annual growth rate (CAGR).
- [By John Emerson]
Open any Berkshire Hathaway (BRK.A)(BRK.B) annual letter and the first thing you see will be a listing of the yearly gains in the book value per share of BRK.A from 1965 to the present year. At the bottom of the year-by-year synopsis lies the compounded annual growth rate (CAGR) of those gains in equity. Later in the article I will show the mathematical formula for calculating those compound gains.
Top 10 Healthcare Technology Companies To Own In Right Now: Bell AG (BELL)
Bell AG is a Switzerland-based company that is primarily engaged in the production and distribution of meat. The Company has seven product groups. The Fresh Meat product group is involved in the supply of self-service meat products for the retail trade and products for the restaurant trade, as well as Vaudois specialties. The Charcuterie (own and purchased) product groups offer ready-cooked products, both under the Bell brand and under a number of customers' own brands. The Poultry product group offers various poultry products, as well as specialty meats, such as rabbit, game, ostrich and kangaroo. The Convenience product group offers ready-cooked seasonal convenience products, such as domestic and imported fish. Within the Seafood product group, the Company offers fresh and frozen seafood. Bell AG�� brands include Abraham, Zimbo and Polette, among others. The Company operates subsidiaries in Switzerland, Germany, France, Spain, Belgium, Hungary and other countries. Advisors' Opinion:- [By Tannor Pilatzke]
Investment ideas are scarce and hard to come by at times. People constantly ask me about companies they work for (Bell) or businesses they purchase a lot of product from (P&G or Coca-Cola), and what I think about the prospects/valuation. When it is not the blue chips in the limelight it certainly is the Netflix��,Tesla's, 3-D printing, and other companies I would classify as speculative. It is not that I am a Grinch, but I do not like giving out investment ideas. Rather, I attempt to give lessons. As Maimonides said, ��ive a man a fish, feed him for a day; teach a man to fish and feed him for a lifetime.��/p>
Top 10 Dividend Stocks To Invest In 2015: Blackstone Mortgage Trust Inc (BXMT)
Blackstone Mortgage Trust, Inc., formerly Capital Trust, Inc. is a self-managed, real estate finance and investment management company that specializes in credit sensitive financial products. The Company�� investment programs are focused on loans and securities backed by commercial real estate assets. The Company invests for its own account and for third parties through a series of investment management vehicles. Capital Trust, Inc. conducts its operations as a real estate investment trust (REIT). In December 2012, the Company announced that an affiliate of Blackstone completed the previously announced acquisition of its investment management business, operated through its subsidiary, CT Investment Management Co., LLC (CTIMCO).
As of December 31, 2009, its $1.8 billion of interest earning assets were comprised of $1.1 billion of loans receivable, including $17.5 million of loans classified as held-for-sale, and $715.2 million of securities. These include 20 impaired loans with an aggregate net book value of $131.0 million ($608.4 million gross carrying value, net of $477.4 million of reserves), and 11 impaired securities with an aggregate net book value of $27.4 million ($145.7 million gross carrying value, against which it has recorded other-than-temporary impairments of $118.3 million).
Advisors' Opinion:- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
Top 10 Healthcare Technology Companies To Own In Right Now: Taylor Morrison Home Corp (TMHC)
Taylor Morrison Home Corporation, incorporated on November 15, 2012, is a homebuilder in North America. The Company operates under its Taylor Morrison brand in the United States and under its Monarch brand in Canada. Its business is organized into three geographic regions: East, West and Canada. Its East region consists of its Houston, Austin, North Florida and West Florida divisions. Its West region consists of its Phoenix, Northern California, Southern California and Denver divisions. Its Canada region consists of its operations within the province of Ontario, primarily in the Greater Toronto Area (GTA) and also in Ottawa and Kitchener-Waterloo, and offers both single-family and high-rise communities.
As of September 30, 2012, the Company offered homes in 122 active selling communities and had a backlog of 4,205 homes sold but not closed, including 903 homes in unconsolidated joint ventures. During the year ended September 30, 2012, the Company closed 2,586 homes, consisting of 1,880 homes in the United States and 706 homes in Canada, including 204 homes in unconsolidated joint ventures.
Our Homes
The Company offers a range of homes to consumers in its markets, ranging from entry-level to luxury homes. The Company market single-family homes with many amenities to entry-level through move-up homebuyers. The Company has developed a number of home designs with features such as one-story living and first floor master bedroom suites to appeal to universal design needs, as well as communities with recreational amenities such as golf courses, pool complexes, country clubs and recreation centers. The Company has integrated these designs and features in many of its homes and communities. The Company offers some of the same basic home designs in similar communities and engages unaffiliated architectural firms to develop new designs to replace or augment existing ones in order to ensure that our homes reflect current and local consumer tastes.
Warranty Progr! am
The Company offers express written limited warranties on our homes that generally provide for one year of coverage for various defects in workmanship or materials. These warranties are in addition to certain legal warranties (including implied warranties) that may apply in the markets where the Company operates. In Canada, in accordance with regulatory requirements administered by the Tarion Warranty Corporation, the Company offers a limited warranty that generally provides for seven years of structural coverage, two years of coverage for water penetration, electrical, plumbing, heating, and exterior cladding defects, and one year of coverage for workmanship and materials.
Community Development
The Company aims to establish a complete concept for each community the Company develops, beginning with an overall community design and then determining the size, style and price range of the homes and the layout of the streets and individual home sites. In the case of developed communities, after necessary governmental subdivision and other approvals have been obtained, the Company improve the land by clearing and grading it, installing roads, installing underground utility lines and recreational amenities, erecting distinctive entrance structures and staking out individual home sites.
Customer Mortgage Financing
Taylor Morrison Home Funding, LLC (TMHF) provides a number of mortgage-related services to its homebuilding customers through its mortgage lending operations. TMHF�� multi-lender platform included Flagstar Bank, US Bank, SunTrust Bank, Wells Fargo Mortgage and Metlife Home Loans. Revenue was derived from yield spread premiums, broker points and processing fees. The main strategic purpose of TMHF in its business is: to utilize finance as a sales tool as part of the purchase process to ensure a consistent customer experience and assist in maintaining production efficiency; and to influence and assist in determining its backlog and ! to better! manage projected closing and delivery dates for its customers.
Advisors' Opinion:- [By Kris Hudson]
Home-builder initial public offerings have delivered mixed results in the past year. Three are trading below their offering prices: Taylor Morrison Home Corp.(TMHC) is down 3.9% from its IPO price at $21.15. William Lyon Homes is down 3.7% at $24.07. UPC Inc. is down 2.9% at $14.57.
Top 10 Healthcare Technology Companies To Own In Right Now: IDEXX Laboratories Inc (IDXX)
IDEXX Laboratories, Inc., incorporated in 1983, develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company operates through three segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller segments that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
The Company sells a range of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its primary products and services are point-of-care veterinary diagnostic products, consisting of instruments and consumables and rapid assays; veterinary reference laboratory diagnostic and consulting services used by veterinarians; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; practice management systems and services and digital radiography systems used by veterinarians; products that test milk for antibiotic residues and other contaminants, and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market.
Companion Animal Group
The Company markets a range of in-clinic laboratory analyzers for use in providing reference laboratory quality diagnostic results in companion animal veterinary practices, which it refers ! to as the IDEXX VetLab suite of analyzers. The Company sells two chemistry analyzers, the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, that are used by veterinarians to measure levels of certain enzymes and other substances in blood or urine for monitoring health status and assistance in diagnosing physiologic conditions. Both instruments use consumables manufactured for IDEXX by Ortho-Clinical Diagnostics, Inc. (Ortho), a subsidiary of Johnson & Johnson, based on Ortho�� dry slide technology (Catalyst Dx slides, VetTest slides or slides). In addition, the Catalyst Dx analyzer also uses dry slide electrolyte consumables manufactured by IDEXX at OPTI Medical Systems, one of its wholly owned subsidiaries. Blood tests commonly run on these analyzers include glucose, alkaline phosphatase, alanine aminotransferase (ALT), albumin, creatinine, blood urea nitrogen (BUN), and total protein. Tests are sold individually and in prepackaged panels. Both analyzers also run a urine test called urine protein:creatinine ratio, which assists in the detection of early renal disease.
The Catalyst Dx analyzer is the Company�� chemistry analyzer. The Catalyst Dx analyzer allows a veterinarian to run multiple patient samples simultaneously; to run different sample types, including whole blood, plasma, serum and urine; to perform 28 different chemistry and electrolyte tests; and to automatically calculate other parameters and ratios important to blood chemistry analysis. Its VetLyte Electrolyte Analyzer measures three electrolytes-sodium, potassium and chloride-to aid in evaluating acid-base and electrolyte balances and assessing plasma hydration. Its VetStat Electrolyte and Blood Gas Analyzer measures electrolytes, blood gases, glucose and ionized calcium, and calculates other parameters, such as base excess and anion gap. These measurements aid veterinarians in diagnosing various disease states, evaluating fluid therapy choices and measuring respiratory function. The VetStat analyzer ru! ns single! -use disposable cassettes that contain various configurations of analytes. The VetStat analyzer and its cassettes are manufactured by OPTI Medical Systems.
The Company sells three hematology analyzers that assess the cellular components of blood, including red blood cells, white blood cells and platelets (also called a complete blood count (CBC)). These analyzers include the ProCyte Dx Hematology Analyzer, which uses laser-flow cytometry, optical fluorescence and laminar-flow impedance in its analysis; the LaserCyte Hematology Analyzer, which uses laser-flow cytometry technology in its analysis, and the IDEXX VetAutoread Hematology Analyzer. It also sells the Coag Dx Analyzer, which permits the detection and diagnosis of blood clotting disorders. The ProCyte Dx analyzer provides validated results for five species (canine, feline, equine, bovine and ferret) for up to 24 different blood parameters, providing a more complete picture of each patient�� health.
The SNAPshot Dx analyzer provides quantitative measurements of total thyroxine (T4), cortisol and bile acids to assist in the evaluation of thyroid, adrenal and liver function. The SNAPshot Dx analyzer also reads, interprets and records the results of many IDEXX rapid assay SNAP tests, including its canine SNAP 4Dx test, feline SNAP FIV/FeLV Combo test, canine SNAP cPL test, feline SNAP fPL test, SNAP Feline Triple test and canine SNAP Heartworm RT test. The IDEXX VetLab UA Analyzer provides chemical urinalysis and is validated specifically for veterinary use. The IDEXX VetLab Station (IVLS) connects and integrates the diagnostic information from all the IDEXX VetLab equipment and thus provides reference laboratory information management system capability. It sells the IVLS as an integral component of the Catalyst Dx, LaserCyte and ProCyte Dx analyzers and also as a standalone hardware platform.
The IVLS includes a user interface to input patient information, connect with a practice management system and send i! nformatio! n to run the individual analyzers. IVLS also generates one integrated patient report incorporating all of the lab work generated by the IDEXX VetLab suite; stores, retrieves and analyzes historical patient diagnostics data, including SNAP test results; and sends and receives information from practice management systems, including the IDEXX Cornerstone system, as well as a variety of third-party systems. It sells a range of single-use, handheld test kits under the SNAP name. In addition to its single-use tests, it sells a range of microwell-based test kits under the PetChek name for canine heartworm, FIV and FeLV.
The Company offers commercial reference laboratory diagnostic and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, South Africa, China and South Korea and to bioresearch customers in the United States and Europe. The Company provides specialized veterinary consultation, telemedicine and advisory services, including radiology, cardiology, internal medicine and ultrasound consulting. It develops, markets and sells practice management systems, including hardware and software, and services that run certain functions of veterinary clinics, including managing patient electronic health records, scheduling (including boarding and grooming), reminders, billing and inventory management.
The Company markets and sells two digital radiography systems for use in the small animal veterinary hospital: the IDEXX-DR 1417 and the IDEXX I-Vision CR. Its digital radiography systems use IDEXX-PACS and IDEXX EquiView PACS picture archiving and communication system (PACS) software for the viewing, manipulation, management, storage and retrieval of the digital images generated by the digital capture plate. In September 2011, the Company launched IDEXX I-Vision Mobile, an application that allows veterinarians with the IDEXX-DR 1417 and IDEXX I-Vision CR systems, as well as its digital radiography systems, to request, view and send images using an iPa! d or an A! ndroid mobile tablet. This application integrates with its IDEXX-PACS software.
Water
The Company offers a range of products used in the detection and quantification of various microbiological parameters in water. Its principal products are the Colilert, Colilert-18 and Colisure tests, which simultaneously detect the presence of total coliforms and E. coli in water. These organisms are used as indicators of microbial contamination in water. These products utilize indicator-nutrients that produce a change in color or fluorescence when metabolized by target microbes in the sample. Its water tests are used by government laboratories, water utilities and private certified laboratories to test drinking water. The tests also are used in evaluating water used in production processes (for example, in beverage and pharmaceutical applications) and in evaluating bottled water, recreational water, waste water and water from private wells.
Livestock and Poultry Diagnostics
The Company sells diagnostic tests and related instrumentation that are used to detect a range of diseases and to monitor health status in livestock and poultry. Its livestock and poultry diagnostic products are purchased by government and private laboratories that provide testing services to cattle, swine and poultry veterinarians and producers. Its principal products include tests for Bovine Viral Diarrhea Virus (BVDV), Porcine Reproductive and Respiratory Syndrome (PRRS) and Bovine Spongiform Encephalopathy (BSE or mad cow disease). BVDV is a common and contagious viral infection that suppresses the immune system, making the animal susceptible to a host of other infections, impacting beef and dairy production yields as a result. PRRS is a contagious virus causing reproductive problems and respiratory diseases. BSE is a fatal neurodegenerative disease in cattle that causes a spongy degeneration in the brain and spinal cord.
Other
The principal products in the Company�! � Dairy ! business are its SNAP tests used to detect antibiotic drug-residue in milk. Its primary product line for detecting antibiotic residue in milk is SNAP Beta-Lactam, which detects penicillin, amoxicillin, ceftiofur and cephaphirin residues, followed by SNAPduo Beta-Tetra, which detects certain tetracycline antibiotic residues in addition to those detected by the SNAP Beta Lactam test kits. It also sells SNAP tests for the detection of certain other contaminants in milk, such as chemical melamine and Alfatoxin M1.
The Company sells OPTI point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, lactate, BUN and ionized calcium, and to calculate other parameters, such as base excess and anion gap. These analyzers are used primarily in emergency rooms, operating rooms, cardiac monitoring areas and other locations where time-critical diagnostic testing is performed within the hospital setting. The OPTI CCA and OPTI Touch Electrolyte and Blood Gas Analyzers run single-use disposable cassettes that contain various configurations of analytes; the OPTI R Analyzer runs reusable cassettes in various analyte configurations; and the OPTI LION Stat Electrolyte Analyzer runs single-use electrolyte cassettes. OPTI Medical Systems also manufactures its VetStat analyzer and provides the electrolyte module and dry slide reagents that make up the electrolyte testing functionality of the Catalyst Dx analyzer.
The Company competes with VCA Antech, Inc., Abaxis, Inc., Butler, Radiometer A/S, Siemens Medical Solutions Diagnostics, Instrumentation Laboratory, Abbott Diagnostics and Roche Diagnostics.
Advisors' Opinion:- [By Sean Williams]
On the diagnostic side, there isn't a company better equipped to help veterinarians diagnose bone and organ disease, or help veterinarians improve the efficiency of their software, than IDEXX Laboratories (NASDAQ: IDXX ) . From small diagnostic analyzers to high-tech digital imagery and even consultation calls, IDEXX does it all for owners and veterinarians. The best part is that the company's companion diagnostics make up the bulk (83%) of its revenue, so the chance of IDEXX seeing a slowdown in demand appears pretty minimal.
- [By CanadianValue]
Idexx (IDXX) performed well in 2011, generating solid revenue growth and high-teens earnings growth thanks to a slight recovery in the veterinary end market, the ramp up of its new ProCyte hematology instrument, continued share gains in reference laboratories and one-time gains from production animal disease eradication programs in Europe. While we continue to like the company�� prospects and are impressed with its execution in a still sluggish market for animal healthcare, we trimmed our position in 2011 at prices we found attractive given our expectations for the business.
Top 10 Healthcare Technology Companies To Own In Right Now: Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.
The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.
MM-398
MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.
The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.
MM-121
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.
MM-111
MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.
MM-302
MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.
MM-151
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.
Advisors' Opinion:- [By Keith Speights]
Not so merry
Merrimack Pharmaceuticals (NASDAQ: MACK ) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%.
Top 10 Healthcare Technology Companies To Own In Right Now: Fair Isaac Corp (FICO)
Fair Isaac Corporation (FICO), incorporated on May 15, 1987, provides products and services that enable businesses to automate, improve and connect decisions to enhance business performance. The Company operates in three segments: Applications, which include pre-configured Decision Management applications designed for a specific type of business problem or process; Scores, which includes the Company's business-to-business scoring solutions and services, its myFICO solutions for consumers, and associated professional services, and Tools segment, which include software tools that clients can use to create their own custom Decision Management applications, as well as associated professional services. In May 2012, the Company acquired Entiera Inc. In September 2012, it acquired Adeptra Ltd. On April 1, 2013, FICO acquired Infoglide Software Corp.
Applications
The Company develops industry-tailored Decision Management applications, categorized as Applications, which apply analytics, data management and Decision Management software to specific business challenges and processes. These include credit offer prescreening, insurance claims management and others. The Company's Applications primarily serve clients in the banking, insurance, healthcare, and retail sectors. The chief offerings for marketing are the Company's FICO Analytic Offer Manager and FICO Customer Dialogue Manager. These solutions offer a suite of products, capabilities and services designed to integrate the technology and analytic services needed to perform context-sensitive customer acquisition, cross-selling and retention programs and deliver mathematically optimized offers.
The Company provides solutions that enable banks, credit unions, finance companies, installment lenders and other companies to automates and improve the processing of requests for credit or service. The Company provides customer management solutions for banking, where it�� account and customer management product is the FICO TRIAD! Customer Manager. The Company markets and sells TRIAD end-user software licenses, maintenance, consulting services, and strategy designs and evaluation. The Company's fraud management products improve the Company's clients' profitability by predicting the likelihood that a given transaction or customer account is experiencing fraud.
The Company's solutions are designed to detect and prevent a range of fraud and risk types across multiple industries, including credit and debit payment card fraud; e-payment fraud; deposit account fraud; technical fraud and bad debt; healthcare fraud; Medicaid and Medicare fraud, and property and casualty insurance claims fraud, including workers' compensation fraud. FICO fraud solutions protect financial institutions, insurance companies and government agencies from losses and damaged customer relationships caused by fraud and related criminal behavior.
FICO Fraud Predictor with Merchant Profiles is used in conjunction with Falcon Fraud Manager on payment card monitoring for credit and debit to improve fraud detection rates through the inclusion of merchant profiles. In addition to the Falcon products, the Company offers FICO Card Alert Service. Card Alert Service is a solution for fighting ATM debit fraud. The Card Alert Service identifies counterfeit payment cards and reports them to issuers. The Company offers FICO Economic Impact Service, which uses time series modeling of the macro economy to allow lenders to forecast future credit risk performance based on their views of the economy. Adeptra's software as a service (SaaS) platform enables financial services institutions and other businesses to take advantage of the explosion in mobile communication in order to manage risk, fight fraud and improve the customer experience, all in real time.
The Company competes with Acxiom, Epsilon, Equifax, Experian, Harte-Hanks, InfoUSA, KnowledgeBase, Merkle, TargetBase, CGI, NICE Systems, BAE, SAS, ACI Worldwide, Emdeon, Ingenix, ViPS, MedSt! at, Veris! k Analytics and IBM.
Scores
The Company develops credit scores based on third-party data. The Company's FICO Scores are used in most United States credit decisions, by the banks and credit card organizations, as well as by mortgage and auto loan originators. These scores provide a consistent and objective measure of an individual's credit risk. Credit grantors use the FICO Scores to prescreen candidates for solicitation, to evaluate applicants for new credit and to review existing accounts. The FICO Scores are calculated based on scoring models and implemented on third-party data. The version of the FICO Score for United States and Canadian lenders is the FICO 8 Score. The Company's other solutions include The FICO Credit Capacity Index and The FICO Economic Impact Index.
The Company competes with Experian and Experian-Scorex (U.S. partner), TransUnion and TransUnion International, Equifax, VantageScore, CRIF, LexisNexis and ChoicePoint.
Tools
The Company provides software products that businesses use to build their own tailored Decision Management applications. In contrast to its packaged Applications developed for specific industry applications, the Company�� Tools support the addition of Decision Management capabilities to virtually any application or operational system. These tools are sold as licensed software, and can be used by themselves or together to advance a client�� Decision Management initiatives. The Company uses these tools as common software components for its own Decision Management applications. The principal products offered are software tools include Rules Management, Predictive Modeling and Optimization.
The Company competes with IBM, SAS, Pegasystems and Angoss.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Getty Images In just a few months, the American banking sector will begin to experience a massive case of collective amnesia. And it's a predictable amnesia, with predictable consequences. According to FICO (FICO), negative financial information -- late payments, bankruptcies, foreclosures, collection accounts, etc -- will generally disappear from your credit report after seven years. You probably already knew this: Personal finance experts talk about it often when discussing credit scores, bankruptcy, or a host of other money issues. But let's do the math. In 2008, the worst financial crisis since the Great Depression hit this country. It led to a record number of foreclosure filings beginning -- nearly 3.1 million filings that year. And the trend continued, with millions of homes foreclosed each subsequent year. Fast forward to 2015, when the first of the great recession foreclosures will start to vanish from credit reports. Credit scores improve as time elapses and your score can experience a big improvement when a major negative item drops off your report. According to Experian (EXPN) data provided to the New York Federal Reserve, the average credit score in the second quarter of 2014 reached 698, the highest level in the last 10 years. We can expect those averages to keep rising as the defaults, delinquencies and foreclosures of the Great Recession begin to be wiped from people's credit records. In addition, housing prices have started improving. The Case-Shiller house price index has experienced double-digit increases over the last few years. And, bank losses have improved. For example, JPMorgan Chase (JPM) has reduced its loan loss reserves for mortgages by $1 billion over the last 12 months alone. So, we are experiencing: Rapidly rising credit scores. Increasing property valuations. Improved bank balance sheets. Can you imagine what that means? Fire Up Those Consumer Credit Engines As memories of the Great Recession disappear from credit burea
- [By Rich Smith]
Alamy You've probably heard by now that in some vague way, your credit rating has something to do with the premiums your auto insurance company charges you for coverage. But if you're like me, you've probably never quite understood the details of how this work. Fortunately, the good folks at InsuranceQuotes.com -- a subsidiary of Bankrate (RATE) -- recently published a report that draws back the curtain on this little-understood quirk of the insurance industry. Blame it on FICO Used to be, the rate you paid for insuring your car was tied primarily to demographic and personal factors that were clearly connected to the risk that you'd damage your car and ask the insurance company to pay for it: things like your age, sex, marital status, and driving history. It won't surprise anyone that younger, unmarried men are more likely to be risky drivers than soccer moms, and should therefore pay higher premiums. But about 20 years ago, the folks at Fair Isaac Corporation (FICO) found a correlation between low credit scores and a higher risk of filing an insurance claim. That's not causation, of course -- having bad credit doesn't somehow cause you to crash your car. But according to FICO, "people who choose to effectively manage their finances are also less likely to have future insurance losses." Conversely, there is a "statistical correlation between a person's credit score and the likelihood that he or she will file an auto insurance claim in the future." Suddenly, FICO had a new way to hawk its credit histories to insurance companies -- and insurance companies had a new excuse to raise your rates. News Flash: Everybody Does It Ever since, insurance companies have used this finding to tweak the rates they charge you for insurance. Today, says InsuranceQuotes, "about 97 percent of U.S. insurance companies" do it. But how do they do it, exactly?
- [By Bloomberg]
Alamy More U.S. banks may soon give free FICO credit scores to millions of card customers along with their monthly bills as Discover Financial Services (DFS) extends the offering to all of its cardholders. FICO (FICO), formerly known as Fair Isaac Corp., is negotiating with some of the largest credit-card issuers, Anthony Sprauve, the San Jose, California-based firm's senior consumer-credit specialist, said in a phone interview, declining to identify the banks. Discover, which began providing the scores to some clients in November, will now furnish them to all consumer cardholders, the lender said in an e-mailed statement. 'Jammed Space' on Statements "It really does come down to the technology-implementation challenges," Sprauve said. "You're talking about millions of customers, a tremendous amount of data, and how do you squeeze more data in an already jammed space" on monthly statements, he said. FICO scores are used in lending decisions, such as for issuing credit cards or setting interest rates on home loans, and are the most widely used credit-scoring formula in the U.S. They previously were available at a cost or through online trial subscriptions.
- [By WWW.DAILYFINANCE.COM]
Jupiterimages.com When it comes to understanding your credit, it can feel as complicated as trying to solve a Rubik's cube. Frustrated by this confusion, many consumers neglect their credit, which can have a devastating impact on their financial futures. A Consumer Action study recently revealed that 27 percent of Americans have never checked their credit report. That's alarming, because it's estimated that a large numbers of consumers have errors on their credit reports that could damage their credit. I found this out several years ago when I found an error -- a canceled account that was being reported as delinquent -- hurting my credit. In my research, I have identified three sneaky things that are hurting other people's credit, too. Surprisingly, they could be fixed in 15 minutes or less. First, you need to get your credit report, and you should go to AnnualCreditReport.com. From this site, you can request your free credit report once a year from the three major credit reporting agencies -- (Equifax (EFX), Experian (EXPGY) and TransUnion). You can also access your credit score there, but you'll have to pay a small fee. To get a free credit score, you can go to Credit.com or Creditkarma.com. Keep in mind that these two as well as a lot of other free sites offer a consumer education score, which isn't your actual FICO (FICO) score. This confused even me when I sought to find my real credit score. Your FICO score changes daily, so getting your credit scores from these free sites will give you a good gauge of approximately what your credit score is. 1. Wrong Information The wrong personal information on your credit report could hurt your credit. This could be things like your name, your home address, where you've worked in the past or even your Social Security number. How does a wrong address hurt your credit? Your information may be mixed up with someone else's, especially if you have a common name, or are a "Jr." or "Sr." Or it could indicate identity th
Top 10 Healthcare Technology Companies To Own In Right Now: Biodel Inc (BIOD)
Biodel Inc. (Biodel), incorporated on December 3, 2003, is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).
The Company has two pivotal Phase III clinical trials with its preferred commercial formulation of Linjeta prior to re-submitting the NDA. In August 2011, it completed patient visits and analyzed top-line data from the first Phase 1 clinical trial of two RHI-based formulations. The trial was a single-center, randomized, double-blind, three-period crossover trial in 18 subjects with Type 1 diabetes. The purpose of the trial was to evaluate the pharmacokinetic and pharmacodynamic characteristics and injection site toleration of BIOD-105 and BIOD-107, as compared to the insulin analog marketed as Humalog. The Company conducted Phase I, Phase II and Phase III clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin, which is a branded formulation of RHI or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.
The Company competes with Eli Lilly, Novo Nordisk, Sanofi-Aventis, Halozyme Therapeutics, Inc. and MannKind Corporation.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 specialty biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Biodel (BIOD), which is focused on the development and commercialization of innovative treatments for diabetes. This stock has been hit hard by the bears over the last three months, with shares down by 24%.
If you take a look at the chart for Biodel, you'll notice that this stock is ripping higher here right off its 50-day moving average of $2.32 a share with strong upside volume. Volume on Thursday has so far registered over 750,000 shares, which is well above its three-month average action of 445,084 shares. This move is quickly pushing shares of BIOD within range of triggering a big breakout trade.
Traders should now look for long-biased trades in BIOD if it manages to break out above some near-term overhead resistance levels at $2.52 to $2.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 445,084 shares. If that breakout triggers soon, then BIOD will set up to re-test or possibly take out its next major overhead resistance levels $3 to its 200-day moving average of $3.39 a share. Any high-volume move above $3.39 will then give BIOD a chance to tag $4 a share.
Traders can look to buy BIOD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2.10 a share. One can also buy BIOD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Monica Gerson]
Biodel (NASDAQ: BIOD) is expected to post a Q1 loss at $0.24 per share.
First Majestic Silver (NYSE: AG) is estimated to post its Q1 earnings at $0.10 per share on revenue of $63.35 million.
Top 10 Healthcare Technology Companies To Own In Right Now: Ballard Power Systems Inc.(BLDP)
Ballard Power Systems Inc. engages in the design, development, manufacture, sale, and service of fuel cell products for motive and stationary power applications worldwide. It offers clean energy PEM (proton exchange membrane) fuel cell stacks, modules, and complete systems. The company provides fuel cell products and services for material handling and bus, back-up power, and distributed generation applications; and fuel cell engineering solutions for various fuel cell applications. It also offers carbon-based engineered material products in the form of roll goods as woven carbon fiber textile fabrics or carbon fiber papers primarily for automotive transmissions and gas diffusion layers. Ballard Power Systems Inc., through its interests in Dantherm Power A/S develops clean energy backup power through utilization of hydrogen fuel cell technology; and Automotive Fuel Cell Cooperation Corp. develops fuel cell products for the automotive fuel cell market. The company was founde d in 1979 and is headquartered in Burnaby, Canada.
Advisors' Opinion:- [By Ben Eisen]
Shares of Ballard Power Systems Inc. (BLDP) �gained 5.2% after the fuel-cell maker said it had acquired patents and patent applications from United Technologies Corp. (UTX) . The intellectual property relates to fuel cells for transportation and stationary. The patents cost Ballard 5.1 million of its shares and $2 million in cash. UTC also has a license to use the patent portfolio.
- [By Bryan Murphy]
Had shares of its peers and competitors performed as well, it may not even be worth bringing up. But, Plug Power Inc. (NASDAQ:PLUG) shares have done significantly better than FuelCell Energy Inc. (NASDAQ:FCEL) and Ballard Power Systems Inc. (NASDAQ:BLDP) since the end of March. And, PLUG has performed considerably better than FCEL and BLDP have since mid-August. This is more than "just a little volatility." This is a leader breaking away from the pack after a very long lull. Thing is, there's plenty more room for Plug Power to keep running.
- [By Ben Levisohn]
Shares of FuelCell Energy have fallen 5,6% to $2.52 at 12:48 p.m., while Ballard Power Systems�(BLDP) has dropped 2.8% to $3.46 and Plug Power�(PLUG) has declined 3.5% to $5.28.
Top 10 Healthcare Technology Companies To Own In Right Now: Makism 3D Corp (MDDD)
Makism 3D Corp., incorporated on May 4 2010, is a three dimensional (3D) printer manufacturing company. The Company produces consumer and professional grade 3D printers. The Company�� flagship product, branded as the Wideboy family of printers, offers packaging designed to fit any office or professional space.
Its 3D printers utilize British and German engineered components. Its printers are assembled in Cambridge (United Kingdom).
Advisors' Opinion:- [By John Udovich]
Although the subject of a recent market correction,�3D printing and 3D printer stocks like�3D Systems Corporation (NYSE: DDD), Stratasys, Ltd. (NASDAQ: SSYS), ExOne Co (NASDAQ: XONE)�and Makism 3D Corp. (OTCBB: MDDD) largely remain hot, but what strategy should investors and/or traders alike take moving forward? Just consider the following latest news about the 3D printing industry or�3D printer stocks:
No comments:
Post a Comment